NonprofitsOxfendazole Development Group

Medical Research

Oxfendazole Development Group

BLUE BELL, PA

Total revenue

$23K

Total expenses

$852K

Net assets

$318K

Grants received

$1.8M

3 grants

EIN

811547477

Tax year

2024

Mission

Research and development of pharmaceutical treatments to help eliminate neglected tropical diseases especially oxfendazole through nonclinical work and the conduct of clinical studies

Financials

FY 2024

Revenue

Contributions & grants$869
Program service revenue
Investment income$22K
Other revenue
Total revenue$23K

Expenses

Grants paid
Salaries & benefits
Fundraising
Other expenses$852K
Total expenses$852K
Total assets$318K
Net assets$318K

People

5 listed

NameRoleCompensation

R John Horton

President Board Member

Board

5 hrs/wk

Ellen Codd

Treasurer Board Member

Board

20 hrs/wk

Robert H Gilman

Board Member

Board

1 hrs/wk

Timothy Geary

Secretary Board member

Board

4 hrs/wk

Javier Bustos

Board member

Board

3 hrs/wk

Grants received

Showing 3 of 3

FromAmountPurposeYear
$101K
DEVELOP THE DEWORMING MEDICINE FOR USE AGAINST HUMAN DWELLING PARASITIC WORMS
2021
$103K
SUB-AWARD
2017

Funded by

$1.8M from 3 funders · 3 grants · 2017–2022

Silicon Valley Community Foundation

$1.6M · 1 grant · 2022

Johns Hopkins University

$103K · 1 grant · 2017

Details

EIN811547477
NTEE codeH80
Subsection03
Ruling date2016-07
Formed2016
Employees0
Volunteers5
OXFENDAZOLE DEVELOPMENT GROUP — Mission, Financials & Grants Received | Grantivo